MedTrace Logo

Quetiapine for the Treatment of Insomnia in Alzheimer's Disease

NCT00232570 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-05-05

No results posted yet for this study

Summary

The primary hypothesis is that quetiapine will improve sleep in persons with Alzheimer's Disease (AD), with higher doses producing greater total sleep time and sleep efficiency.

Conditions

Interventions

DRUG

quetiapine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • University of Vermont

    lead OTHER

Principal Investigators

  • Clifford Singer, M.D. · University of Vermont

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232570 on ClinicalTrials.gov